Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis,
harnesses the power of the immune system to treat cancer, with unique potential for a …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Background Immune checkpoint inhibitors (ICI) are approved for treatment of recurrent or
metastatic oropharyngeal head and neck squamous cell carcinoma in the first-and second …

Invasive lobular breast cancer (ILC) is the second most common histological breast cancer
subtype, but ILC-specific trials are lacking. Translational research revealed an immune …

Immunotherapy is a standard of care in many solid tumors but many patients derive limited
benefit from it. There is increasing interest toward tumor infiltrating lymphocytes (TILs) since …

Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early
setting of breast cancer, there is a clinical need for predictive markers of response in daily …

Background HER2-low cancers are heterogeneous with different degrees of HER2
expression and hormone receptor (HR) status. Currently, its analysis is mostly focused on …

Simple Summary The aim of our study is to provide a wide perspective on the available
literature data on the immune landscape of breast cancers, focusing on TILs and PD-L1 …

A comprehensive search regarding programmed cell death protein 1 (PD‑1)/programmed
death‑ligand 1 (PD‑L1) inhibitor monotherapy or combination therapy in neoadjuvant …

Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative
breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of …